Sunovion Therapeutics Inc.

📖 Wiki Page

company817 wordssynced 2026-04-02

Sunovion

Overview

flowchart TD companies_sunovion["Sunovion Therapeutics Inc."] style companies_sunovion fill:#4fc3f7,stroke:#333,color:#000 companies_sunovion_0["Funding"] companies_sunovion -->|"includes"| companies_sunovion_0 style companies_sunovion_0 fill:#81c784,stroke:#333,color:#000 companies_sunovion_1["Pipeline Overview"] companies_sunovion -->|"includes"| companies_sunovion_1 style companies_sunovion_1 fill:#ef5350,stroke:#333,color:#000 companies_sunovion_2["Parkinsons Disease Programs"] companies_sunovion -->|"includes"| companies_sunovion_2 style companies_sunovion_2 fill:#ffd54f,stroke:#333,color:#000 companies_sunovion_3["Apomorphine Apokyn"] companies_sunovion -->|"includes"| companies_sunovion_3 style companies_sunovion_3 fill:#ce93d8,stroke:#333,color:#000 companies_sunovion_4["Apomorphine Subcutaneous Infusion ABBV-951"] companies_sunovion -->|"includes"| companies_sunovion_4 style companies_sunovion_4 fill:#4fc3f7,stroke:#333,color:#000 companies_sunovion_5["SEP-363856"] companies_sunovion -->|"includes"| companies_sunovion_5 style companies_sunovion_5 fill:#81c784,stroke:#333,color:#000

Sunovion is a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd., headquartered in Marlborough, Massachusetts. The company specializes in central nervous system (CNS) therapeutics and has a significant focus on movement disorders, particularly Parkinson's disease (PD)[@sunovion].

...

Sunovion

Overview

Mermaid diagram (expand to render)

Sunovion's most notable contribution to Parkinson's disease treatment is apomorphine, which remains the only FDA-approved dopamine agonist for rescue therapy in PD patients experiencing "off" episodes. The company continues to develop novel formulations and delivery systems for Parkinson's disease management["@apomorphine"].

Funding

Parent: Sumitomo Pharma (TSE: 4506)
Acquired: 2021 by Sumitomo ($2.6B)

Pipeline Overview

| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| Apomorphine (Apokyn) | Dopamine agonist | Parkinson's Disease | Approved | Marketed |
| Apomorphine SL (Sumatriptan) | Dopamine agonist | Parkinson's Disease | Phase 3 | Completed |
| Apomorphine subcutaneous infusion | Continuous dopaminergic stimulation | Parkinson's Disease | Phase 3 | Active |
| SEP-363856 | Trace amine receptor agonist | Parkinson's Disease | Phase 2 | Active |

Parkinson's Disease Programs

Apomorphine (Apokyn)

Apomorphine is a non-selective dopamine agonist with high affinity for D1, D2, D3, D4, and D5 receptors. Unlike oral dopamine agonists, apomorphine can be administered subcutaneously and provides rapid onset of action, making it effective for treating "off" episodes in PD patients[@apomorphine2005].

Approved Formulations:

Apokyn (injectable): Subcutaneous injection for acute rescue therapy
Apomorphine nasal spray: Under development for rapid "off" rescue

Clinical Use:

Apomorphine is indicated for the treatment of hypomobility ("off") episodes in patients with advanced Parkinson's disease who have an inadequate response to other therapies. It provides onset of action within 10 minutes and effect duration of approximately 60-90 minutes[@apokyn2004].

Apomorphine Subcutaneous Infusion (ABBV-951)

ABBV-951 (formerly known as ABBV-951, foslevodopa/foscarbidopa) is a subcutaneous infusion therapy developed through Sunovion's partnership with AbbVie. This continuous delivery system provides steady dopaminergic stimulation, potentially reducing motor complications[@abbv].

Rationale:

Continuous subcutaneous delivery eliminates oral medication fluctuations
Reduces "off" time and increases "on" time
May improve motor complications and dyskinesias
Suitable for patients with advanced PD

Clinical Status:

Phase 3 trials completed
Submitted for regulatory approval

SEP-363856

SEP-363856 is a novel trace amine-associated receptor 1 (TAAR1) agonist developed by Sunovion. Unlike traditional dopamine agonists, TAAR1 activation offers a non-dopaminergic mechanism for PD treatment, potentially avoiding dopaminergic side effects like dyskinesias[@sep2020].

Mechanism:

Activates trace amine receptors in the brain
Modulates monoamine neurotransmission
Non-dopaminergic mechanism
Potential for disease modification

Clinical Status:

Phase 2 trials in Parkinson's disease
Investigational new drug (IND) active

Autonomic Dysfunction in Parkinson's Disease

Sunovion's Parkinson's disease programs address autonomic dysfunction manifestations:

Apomorphine and Autonomic Symptoms

Apomorphine therapy provides benefits for several autonomic aspects of PD:

OFF-time Reduction: Reducing "off" episodes decreases catecholamine fluctuations that can worsen orthostatic hypotension
GI Function: Stable dopaminergic stimulation may improve gastrointestinal motility
Urinary Control: Better motor symptom control can reduce urinary urgency associated with mobility struggles

ABBV-951 (Foslevodopa/Foscarbidopa) Subcutaneous Infusion

Continuous subcutaneous delivery offers particular advantages for autonomic function:

Stable Plasma Levels: Eliminates oral medication peaks and valleys that can trigger autonomic symptoms
Blood Pressure Stability: Reduces hypotensive episodes associated with medication timing
Sleep Quality: Overnight continuous delivery may improve overnight motor symptoms that disrupt sleep

SEP-363856 (TAAR1 Agonist)

The novel non-dopaminergic mechanism may offer autonomic benefits:

Different side effect profile compared to dopamine agonists
Potential for treating PD patients with autonomic dysfunction
Non-dopaminergic approach may avoid orthostatic hypotension associated with some dopamine agonists

Research Programs

Novel Delivery Systems

Sunovion is developing advanced delivery technologies for Parkinson's disease:

Subcutaneous depot formulations: Long-acting injectables
Intranasal delivery: Rapid-onset rescue therapy
Transdermal patches: Continuous drug delivery

Neuroprotective Approaches

The company is investigating neuroprotective strategies:

[Alpha-synuclein](/proteins/alpha-synuclein) aggregation inhibitors
[Mitochondrial](/mechanisms/mitochondrial-dysfunction) protectants
[Neuroinflammation](/mechanisms/neuroinflammation) modulators

Partnerships

| Partner | Focus Area | Programs |
|---------|------------|----------|
| AbbVie | Continuous infusion | ABBV-951 |
| Sumitomo Pharma | Global development | All programs |
| External academia | Basic research | Various |

Financial Information

Parent company: Sumitomo Pharma Co., Ltd.
Market cap (parent): ~$5 billion (2024)
R&D focus: CNS disorders
Employees: ~1,500

Key Personnel

Miyuki Matsuda - President, Sunovion
John B. Osborn - Chairman
Toshiaki Ise - CEO, Sumitomo Pharma Americas

Cross-References

[Parkinson's Disease](/diseases/parkinsons-disease)
[Dopamine](/mechanisms/dopaminergic-signaling) Agonists
Apomorphine
Roche
AbbVie
Denali Therapeutics
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Dopamine Signaling](/mechanisms/dopamine-signaling)
[Apomorphine](/therapeutics/parkinsons-disease-treatment)
[Autonomic Dysfunction in Parkinson's Disease](/diseases/autonomic-dysfunction-in-corticobasal-syndrome)
[Multiple System Atrophy](/diseases/multiple-system-atrophy)
[REM Sleep Behavior Disorder](/circuits/sleep-wake-circuit)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Unknown, Sunovion Company Overview (n.d.)

Unknown, Apomorphine in Parkinson's Disease - FDA Label (n.d.)

[Apomorphine Mechanism - Jankovic J, et al., Neurology 2005 (2005)](https://pubmed.ncbi.nlm.nih.gov/15911795/)

Unknown, Apokyn Prescribing Information (2004)

Unknown, ABBV-951 Clinical Development - ClinicalTrials.gov (n.d.)

[Unknown, SEP-363856 TAAR1 Agonist - Science Translational Medicine 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32848063/)

📖 View canonical wiki page →